Novo Nordisk A/S

About

Novo Nordisk A/S is a Danish multinational pharmaceutical company listed on Nasdaq Copenhagen (NOVO-B) and, as American Depositary Shares, on the New York Stock Exchange (NVO). With roots dating to 1923 and headquartered in Bagsvaerd, Denmark, it is a global leader in diabetes and obesity care. It is included here as a major industry player whose portfolio intersects with aging biology rather than as a dedicated longevity company. Its GLP-1 receptor agonist semaglutide (Ozempic, Wegovy, Rybelsus) produces large weight loss and cardiometabolic improvement, and the SELECT cardiovascular outcomes trial in older adults with overweight and established cardiovascular disease reduced major adverse cardiovascular events; a post hoc analysis reported attenuation of a proteomic dementia-risk signature. The dedicated Alzheimer's trials evoke and evoke+ improved some disease biomarkers but did not slow clinical progression, tempering expectations for direct disease modification in established disease.

Rating breakdown

Aggregate 62/100 · rank #4 in the commercial table full ratings →

Expand a signal to see what contributes to it.

Key outputs

• product Semaglutide (Ozempic / Wegovy / Rybelsus): GLP-1 receptor agonist; the SELECT trial reduced major adverse cardiovascular events in older adults with overweight and cardiovascular disease without diabetes, with a post hoc signal of attenuated dementia-risk proteomics ↗ 2023
• other evoke and evoke+ trials: largest, longest GLP-1 studies in a neurodegenerative disease (oral semaglutide in early Alzheimer's); biomarker improvement but no slowing of clinical progression ↗ 2025

Registered clinical trials

109 trials list this organisation as lead sponsor ClinicalTrials.gov ↗

• Health Assessment of Low Glycaemic Index - High Protein Rice to Enhance Glycemic Control Through Nutrition ↗ NA · NOT_YET_RECRUITING · 2026-10-01
• Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema ↗ PHASE3 · NOT_YET_RECRUITING · 2026-09-16
• Safety and Immunogenicity Study of a Multivalent Gonorrhoea Vaccine ↗ PHASE1 · RECRUITING · 2026-08-19
• A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight ↗ PHASE3 · WITHDRAWN · 2026-06-22
• Prevalence and Overlap of Cardiovascular, Kidney, and Metabolic Diseases in Korea: A Population-based Study ↗ ENROLLING_BY_INVITATION · 2026-06-08
• A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity ↗ PHASE1 · RECRUITING · 2026-04-30
• A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes ↗ PHASE2 · RECRUITING · 2026-04-17
• Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health) ↗ PHASE1 · RECRUITING · 2026-04-10

Showing 8 of 109 registered trials.

Financial

Market cap

USD 169.29B · NVO (2026-09-29)

Key people

Research fields

Links